Raymond James on Relay (RLAY): ' ~60% upside to Relay’s current stock price, and we think with further derisking for a 1L breast cancer study that is conservative'

March 20, 2026 9:48 AM

Raymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Relay Therapeutics (NASDAQ: RLAY).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found